ALNOV:EPA
Novacyt SA
0,44 €
arrow_downward
-0,68%(-0,0030) 1 d.
19. nov., 13:12:09 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,44 €
Augsta
0,44 €
Zema
0,44 €
Tirgus kapitalizācija
32,08 milj.
Vid. apjoms
136,90 tūkst.
Apjoms
45,82 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,44 €
Augsta
0,44 €
Zema
0,44 €
Tirgus kapitalizācija
32,08 milj.
Vid. apjoms
136,90 tūkst.
Apjoms
45,82 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Barron's
·
pirms 49 minūtēm
Sell the S&P 500 Because the AI Bubble Is About to Burst, Analyst Says. Buy This Instead.
Yahoo Finance
·
pirms 2 stundām
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
MarketWatch
·
pirms 21 minūtes
Stock Market Today: Nasdaq to lead Dow and S&P 500 higher as tech rallies on Anthropic IPO optimism; Nvidia stock gains; Walmart earnings on tap: live updates
Los Angeles Times
·
pirms 15 stundām
A fifth straight drop for the S&P 500 drags Wall Street to its longest losing streak since June
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietnenovacyt.com